EGFR Inhibitor Generations Compared: First, Second and Third

First Generation: Reversible ATP-Competitive Inhibitors

Gefitinib and erlotinib bind reversibly in the ATP pocket of the EGFR kinase. They are highly active against exon 19 deletions and L858R, but they inhibit wild-type EGFR to a similar degree, and their reversible binding is readily outcompeted once the T790M mutation raises the kinase's affinity for ATP.

T790M emerges in roughly half of tumours that progress on a first-generation inhibitor and was the main reason a further generation was needed.

Second Generation: Irreversible, Pan-ErbB

Afatinib and dacomitinib bind covalently and inhibit the whole ErbB family (EGFR, HER2, HER4). This broadens activity, including against some uncommon EGFR mutations, but the covalent pan-ErbB action also increases wild-type-driven skin and gastrointestinal toxicity, which limits dosing.

Because they still bind wild-type strongly, second-generation drugs do not reliably cover T790M at tolerable doses.

Third Generation: Mutant-Selective and Covalent

Osimertinib is covalent like the second generation but is designed to prefer sensitising and T790M-mutant EGFR over wild-type. That mutant selectivity allows effective inhibition of the resistance mutation with less wild-type toxicity, plus better central nervous system exposure.

This combination is why third-generation inhibition is often used first line rather than reserved for T790M-positive relapse.

Resistance Shifts With Each Generation

The dominant resistance mechanism depends on the drug. After first-generation inhibitors it is often T790M. After third-generation inhibition, T790M is usually absent and the picture is dominated by the C797S mutation, bypass-pathway activation (MET, HER2, RAS-MAPK, PI3K) and histologic transformation.

Sequencing decisions therefore rest on which alteration is present at progression, not on the generation alone.

Practical Selection and Monitoring

In routine first-line practice for a common sensitising mutation, a third-generation inhibitor is the usual choice on the strength of longer survival and better protection against brain relapse. Earlier generations stay relevant when a third-generation drug is unavailable, when an uncommon mutation has better-documented response to afatinib, or when access and cost dominate the decision.

Monitoring across the class centres on the skin and gastrointestinal tract, liver enzymes, and — for osimertinib in particular — cardiac function and the QT interval. Diarrhoea and rash are managed proactively, and a planned dose reduction is preferred to repeated interruptions. New or worsening breathlessness prompts assessment for drug-induced pneumonitis before treatment continues.

Key Takeaways

• ·First-generation EGFR inhibitors are reversible and wild-type-sparing only modestly; T790M defeats them.
• ·Second-generation drugs are covalent and pan-ErbB but limited by wild-type toxicity.
• ·Third-generation osimertinib is mutant-selective, covers T790M and the CNS, and shifts resistance to C797S and bypass routes.